image dons

I make a donation

ADMIRAL

National multicentric trial aiming to evaluate the impact of Abciximab versus placebo in patients with an acute coronary syndrome with ST segment elevation and treated with angioplasty

Terminée

La Grande Journée du Coeur (22 juin 2022)
Attention : plus que quelques places restantes !

Colloquium : Pathologies cardiaques de la femme (15 novembre 2022)
Inscriptions ouvertes !

logo étude

objectif

Impact of Abciximab versus placebo in patients with an acute coronary syndrome with ST segment elevation and treated with angioplasty

date de réalisation

1999

nombre de patients

300

nombre de centres participants

26 French centers

type de financement

Private (Lilly)

Publications

  • Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
    G Montalescot, P Barragan, O Wittenberg, P Ecollan, S Elhadad, P Villain, J M Boulenc, M C Morice, L Maillard, M Pansiéri, R Choussat, P Pinton, ADMIRAL Investigators
    Publicated in The New England Journal of Medecine
  • Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention
    J P Collet, G Montalescot, C Lesty, Z Mishal, J Soria, R Choussat, G Drobinski, C Soria, P Pinton, P Barragan, D Thomas
    Publicated in Circulation

Autres études

+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.
+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.
+

ACORES-2

En cours


Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.